List of bibliographic references
Number of relevant bibliographic references: 14.
| Ident. | Authors (with country if any) | Title |
|---|
| 000034 (2011) |
James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada] | The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease |
| 000273 (2010) |
Marta G. Vu Ckovi [États-Unis] ; Quanzheng Li [États-Unis] ; Beth Fisher [États-Unis] ; Angelo Nacca [États-Unis] ; Richard M. Leahy [États-Unis] ; John P. Walsh [États-Unis] ; Jogesh Mukherjee [États-Unis] ; Celia Williams [États-Unis] ; Michael W. Jakowec [États-Unis] ; Giselle M. Petzinger [États-Unis] | Exercise elevates dopamine D2 receptor in a mouse model of Parkinson's disease: In vivo imaging with [18F]fallypride |
| 000337 (2009) |
David A. Price [États-Unis] ; Alex A. Martinez [États-Unis] ; Alexandre Seillier [États-Unis] ; Wouter Koek [États-Unis] ; Yolanda Acosta [États-Unis] ; Elizabeth Fernandez [États-Unis] ; Randy Strong [États-Unis] ; Beat Lutz [Allemagne] ; Giovanni Marsicano [France] ; James L. Roberts [États-Unis] ; Andrea Giuffrida [États-Unis] | WIN55,212‐2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mouse model of Parkinson’s disease |
| 000343 (2009) |
Chen [États-Unis] ; Swope [États-Unis] ; Dashtipour [États-Unis] ; Lyons [États-Unis] | Transdermal Rotigotine: A Clinically Innovative Dopamine‐Receptor Agonist for the Management of Parkinson's Disease |
| 000535 (2008) |
Peter A. Lewitt [États-Unis] ; M. Guttman [Canada] ; James W. Tetrud [États-Unis] ; Paul J. Tuite [États-Unis] ; Akihisa Mori [Japon] ; Philip Chaikin [États-Unis] ; Neil M. Sussman [États-Unis] | Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005) |
| 000647 (2006) |
Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bédard [Canada] ; Thérèse Di Paolo [Canada] | Prevention of levodopa‐induced dyskinesias by a selective NR1A/2B N‐methyl‐D‐aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin |
| 000651 (2006) |
Monzy Thomas ; Jennifer M. Harrell [États-Unis] ; Yoshihiro Morishima [États-Unis] ; Hwei-Ming Peng [États-Unis] ; William B. Pratt [États-Unis] ; Andrew P. Lieberman [États-Unis] | Pharmacologic and genetic inhibition of hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction |
| 000989 (2000) |
Nuria Durany [Espagne, Allemagne, États-Unis] ; Robert Zöchling [Allemagne] ; Karl W. Boissl [Allemagne] ; Werner Paulus [Allemagne] ; Gerhard Ransmayr [Autriche] ; Thomas Tatschner [Allemagne] ; Walter Danielczyk [Autriche] ; Kurt Jellinger [Autriche] ; Jürgen Deckert [Allemagne] ; Peter Riederer [Allemagne] | Human post-mortem striatal α4β2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome |
| 000A81 (1998) |
Schneider [États-Unis] ; M. Van Velson [États-Unis] ; F. Menzaghi [États-Unis] ; G. K. Lloyd [États-Unis] | Effects of the nicotinic acetylcholine receptor agonist SIB‐1508Y on object retrieval performance in MPTP‐Treated monkeys: Comparison with levodopa treatment |
| 000C85 (1993) |
Jeffrey N. Joyce [États-Unis] | Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease cases |
| 000D29 (1991) |
Ahlskog ; Elliott Richelson ; Albert Nelson ; Patrick J. Kelly ; Haruo Okazaki ; Gertrude M. Tyce ; Jon A. Van Heerden ; Susan L. Stoddard [États-Unis] ; Stephen W. Carmichael | Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients |
| 000D33 (1991) |
Elliott J. Mufson [États-Unis] ; Lesa N. Presley [États-Unis] ; Jeffrey H. Kordower [États-Unis] | Nerve growth factor receptor immunoreactivity within the nucleus basalis (Ch4) in Parkinson's disease: reduced cell numbers and co-localization with cholinergic neurons |
| 000D49 (1990) |
Cedarbaum [États-Unis] ; Mary Clark [États-Unis] ; Linda H. Toy [États-Unis] ; Alison Green-Parsons [États-Unis] | Sustained‐release (+)‐PHNO [MK‐458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2‐receptor agonist administered as a long‐acting formulation |
| 000E21 (1986) |
Mark Guttman [Canada] ; Seeman [Canada] ; Gavin P. Reynolds ; Peter Riederer [Autriche] ; Kurt Jellinger [Autriche] ; Wallace W. Tourtellotte [États-Unis] | Dopamine D2 receptor density remains constant in treated Parkinson's disease |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/USA/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/USA/Analysis/Title.i -k "receptor"
HfdIndexSelect -h $EXPLOR_AREA/Data/USA/Analysis/Title.i \
-Sk "receptor" \
| HfdSelect -Kh $EXPLOR_AREA/Data/USA/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= USA
|étape= Analysis
|type= indexItem
|index= Title.i
|clé= receptor
}}
| This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024 |  |
